Presenters:
There is significant promise for targeted alpha therapy to benefit advanced stage cancer patients. Recent publications have reported impressive patient responses. Molecular imaging is uniquely suited to guide translation of targeted alpha therapy.
In this webinar, we will review alpha radionuclides, chemistry, tumor kinetics/penetration/internalization, translational and clinical aspects of targeted alpha therapy and how molecular imaging can be used to guide clinical translation and patient therapy.
Chaitanya Divgi is a nuclear medicine physician-scientist with 30+ years experience in Ivy League institutions leading programs in Nuclear Oncology imaging & therapy. Dr. Divgi leads the scientific and clinical aspects of oncologic imaging, with a focus on drug development design. Previous experience includes over twenty years at Memorial Sloan Kettering Cancer Center, since 2001 as a professor of Radiology (Nuclear Medicine) and Internal Medicine (Immunology); Chief, Molecular Imaging and Nuclear Medicine and Professor, Radiology and Radiation Oncology at the University of Pennsylvania, followed by Vice Chair Radiology- Research at Columbia University, City of New York. He holds an MD from Bangalore University, India. Chaitanya trained in Nuclear Medicine at the Bhabha Atomic Research Centre in Bombay, India, and again at MSKCC, New York.
Dr. Ilovich leads the development of imaging agents and biomarkers in pre-clinical and first-in-human stages. He is an expert in the development and evaluation of novel radiolabeled agents for both imaging and targeted radiotherapeutics with a focus on oncology and immuno-oncology. He leads a team of multi-disciplinary scientists and oversees all scientific aspect of non-clinical development and IND writing and contributes to clinical design and implementation of clinical trials.